Trial Profile
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma An Open-Label, Single-center, Single-arm Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Jun 2022 Results assessing activity and tolerability of apatinib in patients with recurrent advanced melanoma, published in the Oncologist.
- 31 May 2020 Results (n=17) assessing efficacy and safety of apatinib in patients with recurrent or refractory melanoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Status changed from recruiting to completed.